New antibody shows promise for Hard-to-Treat GVHD
NCT ID NCT03604692
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial tested a drug called axatilimab in 41 people with chronic graft-versus-host disease (cGVHD), a complication of stem cell transplants where donor cells attack the patient's body. Participants had already tried at least two other treatments. The study aimed to find a safe dose and see if the drug could improve symptoms. Results showed some patients had partial or complete responses, offering hope for a new treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axatilimab (also called Niktimvo or SNDX-6352), an antibody that targets immune cells involved in chronic graft-versus-host disease
What this could lead to
If successful, axatilimab could offer a new treatment option for people with chronic graft-versus-host disease who have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 41 participants, so results may not apply to everyone. Side effects and lack of lasting benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
-
University of Minnesota Medical Center
Minneapolis, Minnesota, 55455, United States
-
University of Utah Health Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37212-3505, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States